Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Immunotherapy delivered by blinatumomab improves survival in acute lymphoblastic leukemia patients

Max Topp • 9 Jun 2016
EHA 2016
Acute Lymphoblastic Leukemia Antibodies Blinatumomab

Press brief by Max Topp, MD of the University of Würzburg, Würzburg, Germany, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

More from Max Topp

1:54
Brexu-cel in the treatment of R/R MCL: insights from the ZUMA-2 and ZUMA-18 trials
Max Topp • 10 Dec 2023
2:09
CAR T-cell therapy going forward
Max Topp • 8 Mar 2019
1:11
The importance of registering CAR T-cell patient data
Max Topp • 28 Feb 2019
2:56
Dealing with CAR T-cell therapy neurotoxicity
Max Topp • 28 Feb 2019

Related Videos

1:03
Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL
Elias Jabbour • 10 Dec 2023
2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
2:36
A CD38-targeting bispecific antibody in the treatment of R/R T-ALL
Guru Subramanian Guru Murthy • 10 Dec 2023
3:13
Targeting CD38 with a bispecific antibody to treat R/R AML: a Phase I trial
Guru Subramanian Guru Murthy • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals